Top Story Today
Lilly Bets $1.9B on RNA Exon Editing That Leaves Your DNA Untouched
Eli Lilly committed up to $1.9 billion to Ascidian Therapeutics for a technology that fixes genetic errors by swapping defective chunks of RNA, never touching the underlying DNA. The target: inherited kidney diseases, where over 3.5 million Americans may carry a causative mutation and almost no treatments exist. A single Ascidian editor can replace more than 20 exons at once, potentially covering dozens of mutations with one therapy. Roche inked a similar billion-dollar deal with Ascidian last year for neurological diseases, making this the second mega-validation of the platform in under two years.
Why it matters: When two top-five pharma companies both write billion-dollar checks for the same preclinical platform, it signals that RNA exon editing is moving from curiosity to serious therapeutic modality, with implications far beyond kidney disease.
Read more →Clinical Breakthroughs
Legend Biotech Builds CAR-T Cells Inside Patients With a Single Shot
Every patient at the higher dose responded, with an 83% complete response rate and no serious adverse events. Legend's in vivo CAR-T therapy, LB2501, reprograms T cells inside the body after one infusion, skipping the six-week factory process and chemo prep that today's CAR-T therapies require. The data are early (12 patients, weeks of follow-up), but the proof of concept could reshape cell therapy economics entirely.
Read more →Intellia's CRISPR Therapy Aces the First-Ever In Vivo Phase 3 Trial
A single IV infusion cut hereditary angioedema attacks by 87%, and 62% of patients went completely attack-free and medication-free for six months. It's the first time an in vivo CRISPR therapy has cleared a Phase 3 trial. Intellia is now filing a rolling BLA with the FDA, putting it on track for what could be the first approved in vivo gene-editing medicine.
Read more →BMS's Bispecific ADC Crashes the TROP2 Party at ASCO
BMS posted Phase 3 data showing its EGFR/HER3-targeting ADC cut the risk of death by 40% in triple-negative breast cancer, matching or rivaling TROP2 drugs without targeting TROP2 at all. That's a problem for Gilead and AstraZeneca, whose franchises assumed TROP2 would dominate the ADC landscape. The ILD safety rate was just 1.4%, a potential selling point in lung cancer expansions.
Read more →Cytokinetics Hits Both Endpoints in Non-Obstructive HCM, a Space Its Rival Already Lost
After 27 years without an approved product, Cytokinetics just showed its heart drug Myqorzo works in non-obstructive HCM, a condition affecting more patients than the obstructive form it already treats. Bristol Myers Squibb's competing drug failed in this exact space. The data could more than double Cytokinetics' addressable market, and it's running essentially unopposed.
Read more →Deals & Strategy
Travere Bets $1.1B on a BTK Inhibitor to Complement Its Kidney Franchise
Travere licensed civorebrutinib from Everest Medicines for up to $1.1 billion, pairing it with its flagship drug FILSPARI to attack kidney disease from two angles: immune cause and organ damage. The upfront is a manageable $112.5 million, with the rest tied to milestones. The stock dropped 6% anyway, though analysts flagged nearly 50% upside.
Read more →Roche's Oral SERD Fails to Dethrone the First-Line Breast Cancer Standard
Giredestrant couldn't beat aromatase inhibitors in a 992-patient first-line trial, forcing Roche to pivot toward adjuvant (post-surgery) and later-line settings where it has two Phase 3 wins. The FDA accepted a Priority Review application for the adjuvant use. The miss adds to a growing pattern: oral SERDs keep struggling where the old guard still dominates.
Read more →Funding & Financings
Brian Armstrong's Anti-Aging Biotech Raises $435M at $3.1B With Zero Human Data
NewLimit, co-founded by the Coinbase CEO, more than tripled its valuation from about a year ago on the promise of reprogramming old cells to act young again. Founders Fund led the round; Eli Lilly's venture arm came back for seconds. The first human trial, targeting alcohol-related liver disease, is planned for next year. The entire field of epigenetic reprogramming has yet to produce a single therapy tested in people.
Read more →Odyssey Therapeutics Pulls In $304M in a Squeaky-Clean IPO Debut
The inflammation-focused biotech upsized its IPO to $279 million and locked in a same-day $25 million private placement from existing investor TPG. That's $304 million raised on one mid-stage ulcerative colitis drug, on top of approximately $726.5 million in prior private funding. The deal reflects a 2026 IPO market that's open for business, but only for later-stage companies with real clinical catalysts.
Read more →Celcuity Pitches a $10B Vision at ASCO on a Single Cancer Drug
With one positive Phase 3 trial and an FDA decision due July 17, Celcuity's CEO has articulated an aspirational $10 billion company valuation built entirely around gedatolisib. The drug beat Novartis's Piqray in PIK3CA-mutant breast cancer, earning a late-breaking ASCO slot. But the stock fell 25% after data dropped, suggesting investors had priced in a bigger win than a two-to-three-month PFS advantage.
Read more →